Loading...
•
Dec 31, 2020
Atara Q4 2020 Earnings Report
Atara reported financial results and provided operational progress update.
Key Takeaways
Atara Biotherapeutics reported a net loss of $81.3 million for Q4 2020. The company is on track to complete tab-cel® BLA submission in Q3 2021 and ATA188 Phase 2 RCT enrollment, enabling an interim analysis in H1 2022.
On track to complete the rolling tab-cel® BLA submission in Q3 2021 for patients with EBV+ PTLD through active and productive discussions with FDA.
On track with ATA188 Phase 2 RCT enrollment in patients with progressive forms of MS, enabling an interim analysis in H1 2022.
Continued progress on advancing CAR T portfolio, enabling clinical data presentation for mesothelin-targeted ATA2271 in Q4 2021 and IND submission for novel allogeneic CD19 CART ATA3219 in Q4 2021/Q1 2022.
Cash, cash equivalents and short-term investments as of December 31, 2020 totaled $500.7 million.
Forward Guidance
Atara anticipates several key catalysts over the next 18 months, especially the completion of the tab-cel® BLA filing in Q3 2021, significant advancement on the ATA188 program - including long-term clinical data update from the Phase 1 study as well as enrollment progress in the Phase 2 RCT enabling an interim analysis, and preclinical and clinical progress on both the mesothelin and CD19 CAR T programs.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...